Yazar "Arat, M." için listeleme
-
ALLOGENEIC RELATED DONOR STEM CELL TRANSPLANTATION IN AML CR1: ANY RISK FACTOR FOR BETTER SURVIVAL?
Guvenc, S.; Ozcelik, E.; Hindilerden, F.; Hasbal, N.; Serefhanoglu, S.; Kucukkaya, R.; Arat, M. (NATURE PUBLISHING GROUP, 2014)… -
Post-transplant cyclophosphamide based anti-GVHD prophylaxis in patients with all treated in cr with ALLO-HCT from haploidentical vs HLA-mismatched unrelated donors: An ALWP EBMT analysis
Nagler, A.; Labopin, M.; Arat, M.; Remenyi, P.; Koc, Y.; Blaise, D.; Angelucci, E. (Springernature, 2022)[Abstract Not Available] -
TET2 MUTATIONS IN ESSENTIAL THROMBOCYTHEMIA AND PRIMARY MYELOFIBROSIS
Turan, C.; Guvenc, S.; Hancer, V. S.; Hindilerden, F.; Arat, M.; Kucukkaya, R. (FERRATA STORTI FOUNDATION, 2015)… -
TWO NOVEL CALRETICULIN MUTATIONS IN A TURKISH PATIENT WITH PRIMARY MYELOFIBROSIS: C.1116DELA AND C.1120A > C
Guvenc, S.; Hancer, V. S.; Uslu, N.; Arat, M.; Kucukkaya, R. (FERRATA STORTI FOUNDATION, 2015)…